Joined Today: 13

ALXN Alexion Pharmaceuticals, Stock Message Board

All Messages

ALXN Message Board Home | Join The ALXN Group |

#6: Alexion to Present at the UBS Global Life Sciences Conference
TheMachine	September 20, 2008 02:05:20 AM
CHESHIRE, Conn., Sept. 16 /PRNewswire/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion... view message ignore post recommend post

#5: Semi-annual Changes to the NASDAQ Q-50 Index
TheMachine	September 20, 2008 02:05:00 AM
NEW YORK, Sept. 15, 2008 (GLOBE NEWSWIRE) -- The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) announced today the results of the quarterly reranking of the NASDAQ Q-50 Index(sm)... view message ignore post recommend post

#4: ALXn Stock: Alexion to Present at the Morgan Stanley Global Healthcare Unplugged Conference
NewsBot	September 4, 2008 06:04:56 PM
Alexion to Present at the Morgan Stanley Global Healthcare Unplugged Conference CHESHIRE, Conn., Sept. 2 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN stock)... view message ignore post recommend post

#3: Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
NewsBot	April 13, 2008 03:50:32 PM
CHESHIRE, Conn., March 20 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (the 'Company') (Nasdaq: ALXN) today announced that it has completed enrolling patients in its previously... view message ignore post recommend post

#2: Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting
FastFun	November 27, 2007 10:27:09 PM
CHESHIRE, Conn., Nov. 9 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as... view message ignore post recommend post

#1: ALXN News William Blair & Company Initiates Coverage of Alexion Pharmaceuticals, Inc. With Outperform Rating
NewsBot	March 7, 2007 06:15:00 AM
CHICAGO--(BUSINESS WIRE)--William Blair & Company initiated research coverage of Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) ($36.29) with an Outperform rating. Alexion’s... view message ignore post recommend post

Group Home | Login if you want to post a message